Scholarlink

<p>Cervical adenocarcinoma, a significant subtype of cervical cancer, exhibits variable responses to immune checkpoint inhibitors, with some patients experiencing hyperprogressive disease (HPD) characterised by accelerated tumour progression. The molecular and cellular mechanisms underlying HPD remain poorly understood. In this study, we employed single-cell RNA sequencing, T cell receptor profiling, and spatial transcriptomics to longitudinally analyse the tumour and its microenvironment of a single case of cervical adenocarcinoma who developed HPD following anti-PD-1 immunotherapy. Our integrated analyses revealed two key processes associated with HPD: Immunosuppression involving an IFNγ–STAT1–LAG3 axis in T cells, and fibroblast-supported epithelial proliferation and survival via IGF1–IGF1R signalling. Additionally, spatial transcriptomics identified the formation of a distinct pro-metastatic niche post-immunotherapy. These findings nominate LAG3 and IGF1R as candidate therapeutic targets in this patient and demonstrate the power of real-time, multi-modal profiling to identify adaptive hyperprogression mechanisms. Our work illustrates the potential value of longitudinal monitoring in precision oncology and provides a conceptual framework that could be tested for developing personalised interventions for minimal residual disease, non-responders, and HPD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unveiling personalised targets of PD-1 blockade hyperprogression in a cervical adenocarcinoma via longitudinal single-cell and spatial monitoring

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月13日

查看全文
  • Zezhuo Su,
  • Yue Xiao,
  • Li Yang,
  • Yifu Wang,
  • Yanling Qu,
  • Junru Liu,
  • Shunrong Tang,
  • Kelvin Sin Chi Cheung,
  • Jason Pui Yin Cheung,
  • Zhiyuan Xu

摘要

Cervical adenocarcinoma, a significant subtype of cervical cancer, exhibits variable responses to immune checkpoint inhibitors, with some patients experiencing hyperprogressive disease (HPD) characterised by accelerated tumour progression. The molecular and cellular mechanisms underlying HPD remain poorly understood. In this study, we employed single-cell RNA sequencing, T cell receptor profiling, and spatial transcriptomics to longitudinally analyse the tumour and its microenvironment of a single case of cervical adenocarcinoma who developed HPD following anti-PD-1 immunotherapy. Our integrated analyses revealed two key processes associated with HPD: Immunosuppression involving an IFNγ–STAT1–LAG3 axis in T cells, and fibroblast-supported epithelial proliferation and survival via IGF1–IGF1R signalling. Additionally, spatial transcriptomics identified the formation of a distinct pro-metastatic niche post-immunotherapy. These findings nominate LAG3 and IGF1R as candidate therapeutic targets in this patient and demonstrate the power of real-time, multi-modal profiling to identify adaptive hyperprogression mechanisms. Our work illustrates the potential value of longitudinal monitoring in precision oncology and provides a conceptual framework that could be tested for developing personalised interventions for minimal residual disease, non-responders, and HPD.